Navigation Links
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe
Date:10/1/2009

OSAKA, Japan, Oct. 1 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda Pharmaceuticals Nordics AB (Sweden), and Takeda Pharmaceuticals Benelux SPRL (Belgium) - are part of Takeda's strategic global expansion efforts.

"Takeda has a significant opportunity to expand our presence in Mexico, Europe and other priority markets," said Alan MacKenzie, Executive Vice President (EVP) International Operations, Takeda Pharmaceuticals International, Inc. "Executing our territory expansion strategy is an important step toward further globalizing our operations and enhancing our ability to bring important medicines to patients who need them."

The Mexican pharmaceutical market is the 12th largest in the world and accounts for approximately 25 percent of the pharmaceutical sales throughout Latin America. The population in Mexico is increasing, and access to healthcare continues to grow, with the market increasing faster than in the United States and Europe, making it a key region for Takeda's expansion.

Nordics and Benelux are strategically important regions in Europe - Norway, Sweden, Denmark, Belgium and Luxembourg have a combined pharmaceutical market size which accounts for five percent of the European pharmaceutical market. Following the buy-back of Actos® (pioglitazone) in October 2008, Takeda will be distributing Actos in the five countries. The creation of these commercial subsidiaries will further increase Takeda's reach in the regions.

The Turkish pharmaceutical market is one of the largest global pharmaceutical markets, ranked sixth in Europe and 13th worldwide with the fastest forecasted growth rate in Europe over the next five ye
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
2. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
3. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
4. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
5. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
8. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
9. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 The ... the last decade due to the recession, ... and technological advancements. This BCC Research report ... segments of the ambulance and emergency medical ... blood and hemorrhage control devices, equipment used ...
(Date:9/17/2014)... 2014  Decision Resources Group finds that ... for biologic therapy, only a proportion of ... cite patients, discomfort with biological therapy as ... followed by cost-related issues and payer restrictions. ... Janssen Biotech,s Remicade and AbbVie,s Humira are ...
(Date:9/17/2014)... SAN JOSE, Calif. , Sept. 17, 2014 /PRNewswire-iReach/ -- ... laureate of The Tech Awards 2014, one of 10 ... and spark global change. The Tech Awards, a signature program ... Materials, Inc., selected Gradian as one of two laureates in ... http://photos.prnewswire.com/prnh/20140917/146680 Gradian equips hospitals around the ...
Breaking Medicine Technology:Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3
(Date:9/17/2014)... (HealthDay News) -- Present-day Europeans are the descendants ... according to a new study. Previous ... and early European farmers. But, a new genetic ... also the descendants of Ancient North Eurasians. Nearly ... third ancestral group, researchers from Harvard Medical School ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Managing diabetes, quitting smoking, controlling ... can reduce the risk for dementia -- even late ... World Alzheimer Report 2014, commissioned by Alzheimer,s Disease International, ... by 50 percent. The study noted that obesity and ... as well as high blood pressure. The ...
(Date:9/17/2014)... Thompson HealthDay Reporter ... dieters who turn to artificial sweeteners to soothe their ... a new Israeli study suggests. Artificial sweeteners can ... calories, researchers found in human and mouse studies. ... the bacteria residing in the intestines in ways that ...
(Date:9/17/2014)... Mathematics might be able to reduce the need ... to the autoimmune disease lupus. , In a new ... the progression from nephritis kidney inflammation to ... cannot reverse. A kidney biopsy is the only existing ... and its extent. , The model could also be ...
(Date:9/17/2014)... Research has shown that most 18-month-olds learn an ... however, little is known about how children process information ... preschool years. In a new study, a University of ... as they age, and a limit exists as to ... findings could help parents enhance their children,s vocabularies and ...
Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:Babies learn words differently as they age, researcher finds 2
... an effective vaccine against recurrent kidney cancers.// Kidney cancer ... causes about 12,000 deaths in the United States every ... 50s and 60s. Standard treatment involves removal of all ... however, kidney cancer does not respond well to subsequent ...
... shown that a chemotherapy regimen combining vinorelbine (Navelbine) and ... the treatment of hormone-refractory prostate cancer . Specialists say ... in their disease. , However researchers added ... regimen is planned. From a group of 66 patients ...
... Breast cancer survivors can now get up and ... // older women, reported higher body esteem and ... a new study. ,Researchers compared 40 ... sedentary women, all early-stage breast cancer survivors. Regular ...
... has shown that there may be a link of type ... blood has high amounts of iron.// ,In this ... with no history of diabetes, cardiovascular disease or cancer. 700 ... iron concentration of 109 nanograms/milliliter manifested with diabetes whereas ...
... placing a soft plastic tube or catheter into the ... Patients must undergo training for two weeks and ... from the comfort of their home. Hemodialysis patients can ... attached to a blood-cleaning machine at a dialysis center. ...
... replacement therapy among breast cancer survivors has been // stopped ... or new cancers. ,Swedish researchers embarked on the study ... therefore subject to the same menopausal symptoms as other women. ... five years. After the initial 345 women in the study ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
Assetrac allows identification, location, and protection of your assets....
... AgileTrac Surgical Services is a Web-based and ... track, manage, and measure patient flow and ... from admission to discharge. AgileTrac collects patient ... care delays your patient might experience. This ...
... The RoamAlert ECO system provides ... several doors. Each exit is ... When a resident wearing a ... the door will lock; or ...
... Awarix provides an enterprise visibility ... throughput, improve caregiver effectiveness, and increase ... edge RFID location systems and geospatial ... systems to create a real time ...
Medicine Products: